This course provides a comprehensive exploration of cancer biology and genetics. It delves into the characteristics of cancer, the mechanisms of carcinogenesis, and the roles of oncogenes and tumor suppressor genes. Learners will gain insights into cellular signaling pathways and the genetic testing associated with hereditary cancer syndromes. The course also covers tumor genomic profiling, discussing its indications, various types, and future advancements. Additionally, it offers an in-depth look at the common information found in genomic reports and the interplay between somatic variants and drug pairs.

The APSHO Radiation Oncology Committee brings you the APSHO Radiation Oncology APP Network: APP Utilization in Radiation Oncology: Metrics, Challenges, and Best Practices lead by an expert panel on the following key topics:

• Successful Utilization Models and Challenges
• Balancing Clinical and Administrative Roles
• Performance Metrics and Quality Care Alignment
• Professional Development and Career Growth
• Navigating Regulatory and Institutional Hurdles

Tune in to stay updated with the latest advancements in hematology, oncology from the ASCO 2024 conference, and FDA drug approvals.

• Hematology Update from ASCO 2024: Discusses key findings in hematology, including new research and treatment approaches.
• Solid Tumor Oncology Update from ASCO 2024: Covers the latest in solid tumor treatments and their clinical implications.
• Drug Approval Updates: Reviews the newest drug approvals and their potential impact on patient care

By watching this webinar, advanced practitioners will gain critical insights into the latest research, innovative treatments, and new drug approvals, enhancing their ability to provide cutting-edge care to patients.

The Cancer Therapy Prescribing Course is a comprehensive, CE-accredited course for nurse practitioners, PAs, and pharmacists benchmarking the education that advanced practitioners need to safely prescribe cancer therapy. Topics include chemotherapy, targeted therapy, and immunotherapy prescribing best practices.

This course was developed by the Advanced Practitioner Society for Hematology and Oncology (APSHO). Any recommendations contained in this course reflect APSHO's or Harborside's judgement regarding the state of general knowledge and practice in the field as of the date of publication. The recommendations may not be appropriate for use in all circumstances. APSHO and Harborside neither represent nor guarantee that the practices described herein will, if followed, ensure safe and effective patient care. Every healthcare provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications, considering patient specific characteristics, institutional policies and procedures, personnel, and equipment. The provider should always consult the most recent prescribing/product information. Though APSHO and the content creators have applied a rigorous review process to produce an error-free module, inadvertent mistakes can occur during the writing/editing/proofreading process. Information is not guaranteed to be accurate, complete, or current. APSHO, its editors, authors and reviewers cannot be held responsible for any liability incurred as a consequence for the application of any of the contents of this course contents. Figures and tables are used as examples and are not meant to be all-inclusive, nor do they represent endorsement of any particular therapy or institution. Websites mentioned are provided for information only and the website hosts are responsible for their own content and availability.

Key Takeaways:

• Understanding the role of diagnostic radiology in treatment planning and patient management
• Learning about advanced imaging modalities and their impact on radiation therapy
• Enhancing skills in interpreting radiologic findings relevant to radiation oncology

The Safely Prescribing Controlled Substances in Oncology modules by APSHO include 13 comprehensive, and self-paced modules, thoughtfully crafted to equip you with the knowledge and expertise necessary to safely prescribe controlled substances and to understand and manage substance use disorders in the hematology/oncology setting. (These modules will meet the DEA requirement for 8 hours of training on substance use disorder.)  9 CE-Accredited Hours (3.5 pharmacology hours for ANCC accreditation)

The Diversity, Equity, and Inclusion in Oncology modules by APSHO include 8 comprehensive and self-paced modules to equip you with the understanding of health disparities, inequities and structural racism in the hematology/oncology setting and how these affect patient outcomes. (Additionally, one of the modules addresses health disparities and inequities in substance use disorders and this module meets the DEA requirement for training on substance use disorder.) 3.75 CE-Accredited Hours

• Articulate the impact of lung cancer health disparity in various populations 
• Identify the disparities in lung cancer in screening, diagnosis, and treatment 
• Describe the advanced practitioner role in lung cancer screening and the impact on racial and ethnic survival disparities

• Articulate the impact of colorectal cancer (CRC) in Black individuals in terms of mortality
• Identify the disparities in CRC in screening, diagnosis, and treatment
• Describe the advanced practitioner role in screening and the impact on racial and ethnic survival disparities

• Differentiate between health disparity versus health inequity
• Discuss how race, ethnicity, and socioeconomic status contribute to breast cancer disparities 
• Describe the impact of culture, implicit bias, and institutional racism on treatment outcomes and mortality